Anthera Pharmaceutic (NASDAQ:ANTH) shares traded -80.87% down during most recent session to reach at the closing price of $0.5. The stock exchanged hands 39.66 Million shares versus average trading capacity of 1.65 Million shares, yielding a market cap of $7.16 Million. Wall Street analysts covering the stock are projecting that the stock will reach $3.79 within the next 52-weeks. The mean target projections are based on 6 opinions.

Taking a broader look brokerage firms’ analysts on the street with an expectant view have Anthera Pharmaceutic (NASDAQ:ANTH) high price target of $10 and with a conservative view have low price target of $1.75.

Roth Capital “Initiates Coverage On” Anthera Pharmaceutic (NASDAQ:ANTH) in a research note issued to investors on 2/21/18 to Buy with price target of $10.

Additionally on 12/29/16 Jefferies “Downgrades” Anthera Pharmaceutic (NASDAQ:ANTH) to Hold setting price target at $0 and on 12/29/16 Citigroup “Downgrades” the stock to Neutral at $0. Furthermore on 9/17/15 Citigroup “Initiates Coverage on” the stock to Buy at $15.

On the other hand the company has Relative Strength Index (RSI 14) of 26.03 along with Average True Range (ATR 14) of 0.39, Consequently Anthera Pharmaceutic (NASDAQ:ANTH)’s weekly and monthly volatility is 17.66%, 14.59% respectively. The company’s beta value is at 2.17.

In terms of Buy, Sell or Hold recommendations, Anthera Pharmaceutic (NASDAQ:ANTH) has analysts’ mean recommendation of 2.5. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.

According to analysts Anthera Pharmaceutic (NASDAQ:ANTH)’s minimum EPS for the current quarter is at $-0.64 and can go high up to $-0.23. The consensus mean EPS for the current quarter is at $-0.44 derived from a total of 5 estimates from the analysts who have weighed in on projected earnings. However the company reported $-2.03 earnings per share for the same quarter during last year.

Previously Anthera Pharmaceutic (NASDAQ:ANTH) reported $-0.73 earnings per share (EPS) for the quarter, missing the consensus estimate of $-0.66 by $-0.07. The company posted an earnings surprise of -10.6%.

Currently Anthera Pharmaceutic (NASDAQ:ANTH)’s shares owned by insiders are 0.1%, whereas shares owned by institutional owners are 21.3%. However the six-month change in the insider ownership was recorded 152.14%, as well as three-month change in the institutional ownership was recorded 145.74%.

Anthera Pharmaceutic (NASDAQ:ANTH) 52-week high price stands at $5.96 and low price stands at $1.20, its price distance from 52-week high is -91.52% while its distance from 52-week low price is -57.92%. The stock hit its 52-week high on 03/30/17, and 52-week low on 03/12/18.

Anthera Pharmaceutic (NASDAQ:ANTH)’s trailing twelve month revenues are $0, whereas its price to sales ratio for the same period is 0. Its book value per share for the most recent quarter is $-0.44 while its price to book ratio for the same period is 0, as for as the company’s cash per share for the most recent quarter is $0.16, however its price to cash per share ratio for the same period is 3.25. The stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0.